For research use only. Not for therapeutic Use.
VPC-14449(CAT: I012134) is a novel and specific inhibitor targeting the androgen receptor DNA-binding domain (AR-DBD). It effectively inhibits both Y594A and Q592A mutants, blocking the interaction of the androgen receptor (AR) with androgen response elements in the nucleus. This unique mechanism of action makes VPC-14449 a valuable tool for studying AR-mediated transcriptional regulation and its role in prostate cancer and other AR-driven diseases. With high purity and consistent quality, it is ideal for in vitro and in vivo studies, supporting advanced research in oncology and drug development. VPC-14449 is part of a premium range of biochemicals tailored for cutting-edge scientific investigations.
| Catalog Number | I012134 |
| CAS Number | 1621375-32-3 |
| Synonyms | 4-(4-(4,5-Dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine |
| Molecular Formula | C10H10Br2N4OS |
| Purity | ≥95% |
| Target | Androgen Receptor |
| IUPAC Name | 4-[4-(2,4-dibromoimidazol-1-yl)-1,3-thiazol-2-yl]morpholine |
| InChI | InChI=1S/C13H14N2OS/c1-2-4-11(5-3-1)12-10-17-13(14-12)15-6-8-16-9-7-15/h1-5,10H,6-9H2 |
| InChIKey | MRNNJVNMXOZEQC-UHFFFAOYSA-N |
| SMILES | C1COCCN1C2=NC(=CS2)C3=CC=CC=C3 |
